WO2000066156A8 - Death domain containing receptor 5 - Google Patents

Death domain containing receptor 5

Info

Publication number
WO2000066156A8
WO2000066156A8 PCT/US2000/012041 US0012041W WO0066156A8 WO 2000066156 A8 WO2000066156 A8 WO 2000066156A8 US 0012041 W US0012041 W US 0012041W WO 0066156 A8 WO0066156 A8 WO 0066156A8
Authority
WO
WIPO (PCT)
Prior art keywords
domain containing
death domain
containing receptor
proteins
receptor
Prior art date
Application number
PCT/US2000/012041
Other languages
French (fr)
Other versions
WO2000066156A1 (en
Inventor
Jian Ni
Reiner L Gentz
Guo-Liang Yu
Craig A Rosen
Original Assignee
Human Genome Sciences Inc
Jian Ni
Reiner L Gentz
Yu Guo Liang
Craig A Rosen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc, Jian Ni, Reiner L Gentz, Yu Guo Liang, Craig A Rosen filed Critical Human Genome Sciences Inc
Priority to AU48172/00A priority Critical patent/AU4817200A/en
Priority to EP00930329A priority patent/EP1196191A4/en
Priority to JP2000615040A priority patent/JP2002543151A/en
Priority to CA002369371A priority patent/CA2369371A1/en
Publication of WO2000066156A1 publication Critical patent/WO2000066156A1/en
Publication of WO2000066156A8 publication Critical patent/WO2000066156A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The present invention relates to novel Death Domain Containing Receptor-5 (DR5) proteins which are members of the tumor necrosis factor (TNF) receptor family, and have now been shown to bind TRAIL. In particular, isolated nucleic acid molecules are provided encoding the human DR5 proteins. DR5 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of DR5 acitivity.
PCT/US2000/012041 1999-05-04 2000-05-04 Death domain containing receptor 5 WO2000066156A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU48172/00A AU4817200A (en) 1999-05-04 2000-05-04 Death domain containing receptor 5
EP00930329A EP1196191A4 (en) 1999-05-04 2000-05-04 Death domain containing receptor 5
JP2000615040A JP2002543151A (en) 1999-05-04 2000-05-04 Death domain containing receptor 5
CA002369371A CA2369371A1 (en) 1999-05-04 2000-05-04 Death domain containing receptor 5

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US13249899P 1999-05-04 1999-05-04
US60/132,498 1999-05-04
US13323899P 1999-05-07 1999-05-07
US60/133,238 1999-05-07
US14893999P 1999-08-13 1999-08-13
US60/148,939 1999-08-13

Publications (2)

Publication Number Publication Date
WO2000066156A1 WO2000066156A1 (en) 2000-11-09
WO2000066156A8 true WO2000066156A8 (en) 2001-07-26

Family

ID=27384298

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/012041 WO2000066156A1 (en) 1999-05-04 2000-05-04 Death domain containing receptor 5

Country Status (5)

Country Link
EP (1) EP1196191A4 (en)
JP (1) JP2002543151A (en)
AU (1) AU4817200A (en)
CA (1) CA2369371A1 (en)
WO (1) WO2000066156A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7528239B1 (en) 1997-02-13 2009-05-05 Immunex Corporation Receptor that binds trail
US6342369B1 (en) 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
TWI318983B (en) 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
US7476383B2 (en) 2000-05-02 2009-01-13 The Uab Research Foundation Antibody selective for DR4 and uses thereof
US7279160B2 (en) 2000-05-02 2007-10-09 The Uab Research Foundation Combinations of DR5 antibodies and other therapeutic agents
WO2002094880A1 (en) 2001-05-18 2002-11-28 Kirin Beer Kabushiki Kaisha Anti-trail-r antibodies
JP4309758B2 (en) 2001-05-25 2009-08-05 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド Antibodies that immunospecifically bind to TRAIL receptors
WO2003038087A1 (en) 2001-10-04 2003-05-08 Kansai Technology Licensing Organization Co., Ltd. DR5 GENE PROMOTER AND Siah-1 GENE PROMOTER
DE602004022390D1 (en) * 2003-03-26 2009-09-17 Apogenix Gmbh IMPROVED FC FUSION PROTEINS
EP1756162A1 (en) 2004-03-23 2007-02-28 Biogen Idec MA Inc. Receptor coupling agents and therapeutic uses thereof
WO2005114187A2 (en) * 2004-04-23 2005-12-01 The United States Of America As Represented By Thesecretary, Department Of Health And Human Services Methods and compositions for diagnosing aids and other diseases and conditions involving immune system activation
JP5562521B2 (en) 2005-02-02 2014-07-30 ザ ユーエービー リサーチ ファンデーション Agents and methods relating to reducing resistance to apoptosis-inducing death receptor agonists
PE20071101A1 (en) 2005-08-31 2007-12-21 Amgen Inc POLYPEPTIDES AND ANTIBODIES
KR20120101050A (en) 2009-11-05 2012-09-12 더 유에이비 리서치 파운데이션 Treating basal-like genotype cancers
WO2011116344A2 (en) 2010-03-18 2011-09-22 The Uab Research Foundation Targeting cancer stem cells
CA2867631C (en) * 2012-03-28 2019-06-11 Amgen Inc. Dr5 receptor agonist combinations
EP3305812B1 (en) 2013-03-14 2020-06-17 Bristol-Myers Squibb Company Combination of dr5 agonist and anti-pd-1 antagonist and methods of use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010010924A1 (en) * 1997-03-14 2001-08-02 Keith Charles Deen Tumor necrosis factor related receptor, tr6 polynecleotides
CA2285040C (en) * 1997-03-17 2009-01-27 Human Genome Sciences, Inc. Death domain containing receptor 5
AU781952B2 (en) * 1999-05-28 2005-06-23 Genentech Inc. DR4 antibodies and uses thereof
ATE330972T1 (en) * 1999-06-09 2006-07-15 Genentech Inc APO-2L RECEPTOR AGONIST AND CPT-11 SYNERGY EFFECT
TWI318983B (en) * 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof

Also Published As

Publication number Publication date
AU4817200A (en) 2000-11-17
EP1196191A4 (en) 2004-03-24
EP1196191A1 (en) 2002-04-17
CA2369371A1 (en) 2000-11-09
JP2002543151A (en) 2002-12-17
WO2000066156A1 (en) 2000-11-09

Similar Documents

Publication Publication Date Title
WO1998041629A3 (en) Death domain containing receptor 5
AU6250098A (en) Death domain containing receptor 4 (dr4: death receptor 4), member of the tnf-receptor superfamily and binding to trail (ap02-l)
AU6238698A (en) Tumor necrosis factor receptor 5
WO2000066156A8 (en) Death domain containing receptor 5
WO1998030694A3 (en) TUMOR NECROSIS FACTOR RECEPTORS 6α AND 6$g(b)
WO2001055308A8 (en) Nucleic acids, proteins, and antibodies
EP1003767A4 (en) Human tumor necrosis factor receptor tr10
WO2001054472A3 (en) Nucleic acids, proteins, and antibodies
WO2000067793A8 (en) Death domain containing receptor 4
WO2000054651A3 (en) Human tumor necrosis factor receptor-like genes
WO1998027932A3 (en) Cerebellum and embryo specific protein
WO2000024771A3 (en) Nucleic acids encoding osteoprotegerin-like proteins and methods of using same
WO2001055168A8 (en) Nucleic acids, proteins and antibodies
EP1187842A4 (en) Human tumor necrosis factor receptor tr10
WO2001005834A9 (en) Human tumor necrosis factor receptors tr13 and tr14
WO2000043419A3 (en) Exocytosis pathway proteins and methods of use
WO1999042586A3 (en) Exo1 and exo2, exocytotic proteins
WO2002018622A3 (en) TUMOR NECROSIS FACTOR RECEPTORS 6α AND 6$g(b)
WO2002057421A3 (en) Human tumor necrosis factor receptors tr13 and tr14
WO2001055167A8 (en) Nucleic acids, proteins, and antibodies
WO2001055162A8 (en) Nucleic acids, proteins, and antibodies
EP1865061A3 (en) IL-17 homologous polypeptides and therapeutic uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: C1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i
ENP Entry into the national phase in:

Ref document number: 2369371

Country of ref document: CA

Ref country code: JP

Ref document number: 2000 615040

Kind code of ref document: A

Format of ref document f/p: F

Ref country code: CA

Ref document number: 2369371

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000930329

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2000930329

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2000930329

Country of ref document: EP

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)